Article Text

Download PDFPDF

  1. Jonathan Witherick1,
  2. Paul Virgo2,
  3. Juliana Redondo1,
  4. David Cottrell1,
  5. Neil Scolding1,
  6. Claire Rice1
  1. 1Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital
  2. 2Southmead Hospital, Bristol


Release of CD34+ haematopoietic stem cells (HSC) into the peripheral circulation has been demonstrated in patients receiving anti-CD49d monoclonal antibody for the treatment of multiple sclerosis (MS). It is not known whether these cells are mobilised during an acute MS relapse or by treatment with other disease-modifying drugs (DMDs).

We analysed peripheral blood samples from patients with MS including those on disease modifying therapy and during acute relapses. Circulating numbers of CD34/133+ cells were determined using flow cytometry. A novel, multi-channel flow cytometric approach was developed to identify multipotent mesenchymal stromal cells (MSCs).

The finding of mobilisation of CD34+ HSCs with anti-CD49d antibody infusion was replicated. Increases in circulating numbers of CD34+ HSCs were also observed in patients treated with glatiramer acetate and in MS patients experiencing an acute relapse, irrespective of ongoing treatment with DMDs. CD133+ subsets were also increased in all groups. Circulating MSCs were not detected in the peripheral blood of patients or controls.

Our results suggest a role for HSC mobilisation during treatment for MS and in acute relapse. Further work will examine the role of these cells in the pathogenesis of MS and endogenous repair.


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.